Compounded GLP-1 Medications in 2026: What's Legal Now

The 2024–2025 end of shortage-based compounding transformed the market. What's legal now, what isn't, and what it means for patients who were on compounded GLP-1s.

Through 2022–2024, compounded semaglutide and tirzepatide were legally produced at massive scale by pharmacies across the country. Millions of patients accessed these medications at a fraction of the branded cost. Then, in late 2024 and early 2025, the legal basis for that market — the FDA drug shortage list — collapsed. By mid-2025, enforcement discretion for shortage-based compounding had ended. The landscape in 2026 looks very different.

This article covers what actually happened, what's still legal, what isn't, and how patients who have been on compounded medications should think about next steps.

The Legal Framework — Simplified

U.S. law has two distinct legal pathways for pharmacy compounding:

Section 503A — State-Licensed Pharmacies

State-licensed pharmacies can compound medications for specific individual patients based on a valid prescription. This is traditional compounding — what pharmacies did for decades before mass-market compounding existed. 503A compounders can't mass-produce medications or stock shelves with compounded products. They can compound based on documented patient-specific need.

Section 503B — Outsourcing Facilities

503B outsourcing facilities are FDA-registered, inspected, and subject to current Good Manufacturing Practices (cGMP) — similar quality standards to brand manufacturers. They can produce larger batches of medications and sell to healthcare providers without patient-specific prescriptions. But 503B facilities operate under specific restrictions, including restrictions on what products they can make.

The "Essentially a Copy" Rule

Both 503A and 503B are prohibited from compounding products that are "essentially a copy" of a commercially available FDA-approved drug. The rationale: compounding exists to meet individual patient needs that FDA-approved products don't address, not to provide cheaper alternatives to approved products.

The Shortage Exception

When an FDA-approved drug is on the FDA Drug Shortage List, it's considered not "commercially available" for purposes of the essentially-a-copy rule. This allowed compounders to produce semaglutide and tirzepatide at scale while the brand products were unable to meet demand.

When the shortages end, the exception ends. The 2024–2025 transition reflects exactly this.

The Timeline of Change

What Is Still Legal in 2026

Patient-Specific 503A Compounding With Medical Necessity

A 503A pharmacy can still compound semaglutide or tirzepatide for an individual patient when the prescriber documents medical necessity that a commercially available product doesn't meet. Examples of documented necessity that may support compounding:

• Allergy to an inactive ingredient in the branded product
• Need for a specific dose not commercially available
• Need for a formulation variation (e.g., alternative concentration) for specific clinical reasons
• Patient-specific preservative intolerance

These cases are narrower than the mass-market compounding that existed in 2023–2024. The number of legitimate 503A patient-specific compounds is substantially smaller than the pre-2025 compounding market.

FDA-Approved Products From All Manufacturers

Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Rybelsus, Saxenda, and the newly approved Wegovy pill and Foundayo are all available through standard pharmacy channels. Supply is stable.

Manufacturer Direct-to-Consumer Programs

LillyDirect (Zepbound vials, Foundayo) and NovoCare (Wegovy) offer self-pay products at significantly reduced prices — often closer to former compounded prices than to branded pen prices.

What Is No Longer Legal

Shortage-Based Mass-Market Compounding

Large-scale production of semaglutide or tirzepatide by compounding pharmacies without patient-specific documentation of medical necessity is no longer legal. Both 503A and 503B pathways have lost the shortage-based pathway that enabled mass production.

Telehealth-to-Compounded Pipeline Marketing

The business model of telehealth-screen → compounded-semaglutide-prescription → bulk-compounded-product that characterized 2023–2024 is largely no longer legal. Many of these businesses have pivoted to FDA-approved products, shut down, or migrated to gray-area offerings.

"Essentially a Copy" Products

Any compounded product that's identical or nearly identical to an FDA-approved product — same active ingredient, same route, same dosage form, same strength — is prohibited outside very narrow exceptions.

The Ongoing Litigation

The Outsourcing Facilities Association (OFA) has filed legal challenges against FDA's shortage resolution decisions. The tirzepatide lawsuit (Outsourcing Facilities Association v. FDA, 4:24-cv-953) and semaglutide lawsuit (4:25-cv-00174) argue that the FDA's shortage determinations were arbitrary and that compounders should retain authority to produce these products.

Courts have generally declined to block FDA's enforcement actions while the cases proceed. The April 24, 2025 decision denying the plaintiffs' preliminary injunction on semaglutide confirmed that 503A enforcement discretion ending April 22 remained in effect.

What the outcome of full merits litigation will be is uncertain, but as of April 2026, the practical reality is that mass-market compounded semaglutide and tirzepatide is largely unavailable through legitimate channels.

What Patients Who Were on Compounded GLP-1s Have Done

Several transitions have been common:

1. Switch to Branded Medication

Many patients transitioned to Wegovy, Zepbound, Ozempic, or Mounjaro through insurance-covered pathways. This requires getting a new prescription, navigating insurance coverage (including possible prior authorizations), and potentially paying higher copays.

2. Switch to Manufacturer Direct-to-Consumer

LillyDirect's vial-format Zepbound and NovoCare's self-pay Wegovy programs offer significantly reduced prices for patients who don't qualify for insurance coverage. Monthly costs typically $349–$700 depending on dose and program.

3. Switch to Oral GLP-1 Medications

Foundayo (orforglipron) at $149/month starting dose and Wegovy pill at $149/month starting dose have given cost-sensitive patients new oral options.

4. Pursue Documented Medical Necessity

A smaller subset of patients have pursued patient-specific 503A compounding based on documented medical necessity (allergies, non-commercially-available doses, etc.). This is narrower and more regulated than the former mass market.

5. Discontinue Treatment

Some patients stopped GLP-1 therapy rather than pay increased costs. This has resulted in substantial weight regain for many, which is unfortunate but sometimes reflects real financial constraints.

Signs a Provider or Source Is Not Legitimate

For patients navigating the current landscape, some red flags:

• No prescription required — any source offering GLP-1 medications without a prescription is either illegal or selling non-medication products
• No pharmacy license visible — legitimate compounding pharmacies have state and federal registrations
• Unusually low prices — current legitimate pricing floor for compounded semaglutide is higher than 2023 prices; very low prices often indicate research-peptide sources
• Products labeled "research only" — these are not medications; they're chemicals sold under a regulatory loophole
• Unusual product names or formulations — legitimate prescription GLP-1s are branded (Wegovy, Zepbound, etc.) or clearly labeled as compounded semaglutide/tirzepatide from a licensed pharmacy
• No prescriber involvement — any online source that doesn't involve a licensed prescriber evaluating you is not providing legal medication

The Quality Concern

FDA has reported over 775 adverse event reports associated with compounded GLP-1 medications through early 2025 — 455+ for semaglutide and 320+ for tirzepatide. These include dosing errors (from patients self-administering products of inconsistent concentration), infections (from inadequately sterile products), and other harms.

Part of the FDA's rationale for ending the shortage-based compounding pathway was patient safety concerns stemming from the scale of the former market. Legitimate compounding pharmacies maintain quality standards; the larger mass market included variable quality, and the adverse events reflected that variability.

Questions Worth Asking

If you're evaluating GLP-1 access options in 2026:

• Does my insurance cover any FDA-approved GLP-1 product for my specific indication?
• If uninsured or insurance-excluded, what's the LillyDirect or NovoCare pricing for my medication?
• Is an oral option (Foundayo or Wegovy pill) at $149/month a reasonable starting approach for me?
• If I have documented allergies or specific dose needs, does 503A compounding legitimately meet my case?
• If a source is offering what looks like "compounded GLP-1" online, is it a licensed pharmacy with prescriber involvement, or a research-peptide vendor?